UA79235C2 - Il-18 mutant polypeptide, extracted dna coded il-18 mutant polypeptide, vector and pharmaceutical composition - Google Patents

Il-18 mutant polypeptide, extracted dna coded il-18 mutant polypeptide, vector and pharmaceutical composition Download PDF

Info

Publication number: UA79235C2
Authority: UA; Ukraine
Prior art keywords: avr; cells; bek; biu; iem
Prior art date: 2001-03-08

Application number

UA2003109084A

Other languages

English (en)

Ukrainian (uk)

Inventor

Charles Dinarello

Soo Khiun Kim

Original Assignee

Ares Trading Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-03-08

Filing date

2002-08-03

Publication date

2007-06-11

2002-08-03 Application filed by Ares Trading Sa filed Critical Ares Trading Sa

2007-06-11 Publication of UA79235C2 publication Critical patent/UA79235C2/uk

Links

239000013598 vector Substances 0.000 title abstract description 19
108090000765 processed proteins & peptides Proteins 0.000 title abstract description 13
229920001184 polypeptide Polymers 0.000 title abstract description 10
102000004196 processed proteins & peptides Human genes 0.000 title abstract description 10
239000008194 pharmaceutical composition Substances 0.000 title abstract description 6
230000035772 mutation Effects 0.000 abstract description 23
239000002299 complementary DNA Substances 0.000 abstract description 12
230000003993 interaction Effects 0.000 abstract description 4
238000006467 substitution reaction Methods 0.000 abstract description 4
102000003810 Interleukin-18 Human genes 0.000 abstract description 3
108090000171 Interleukin-18 Proteins 0.000 abstract description 3
125000000539 amino acid group Chemical group 0.000 abstract description 2
102000044166 interleukin-18 binding protein Human genes 0.000 abstract 1
108010070145 interleukin-18 binding protein Proteins 0.000 abstract 1
210000004027 cell Anatomy 0.000 description 56
108090000623 proteins and genes Proteins 0.000 description 41
102000004169 proteins and genes Human genes 0.000 description 34
235000018102 proteins Nutrition 0.000 description 32
102220554136 APC membrane recruitment protein 1_E42A_mutation Human genes 0.000 description 28
108020004414 DNA Proteins 0.000 description 26
238000006243 chemical reaction Methods 0.000 description 24
206010028980 Neoplasm Diseases 0.000 description 20
239000002243 precursor Substances 0.000 description 16
230000000694 effects Effects 0.000 description 14
238000004519 manufacturing process Methods 0.000 description 14
102000004127 Cytokines Human genes 0.000 description 13
108090000695 Cytokines Proteins 0.000 description 13
150000001413 amino acids Chemical group 0.000 description 13
108010074860 Factor Xa Proteins 0.000 description 12
108010076504 Protein Sorting Signals Proteins 0.000 description 12
238000003776 cleavage reaction Methods 0.000 description 12
230000014509 gene expression Effects 0.000 description 11
230000007017 scission Effects 0.000 description 11
239000012634 fragment Substances 0.000 description 10
235000010469 Glycine max Nutrition 0.000 description 9
235000001014 amino acid Nutrition 0.000 description 9
229940024606 amino acid Drugs 0.000 description 9
102220553782 APC membrane recruitment protein 1_K89A_mutation Human genes 0.000 description 8
244000068988 Glycine max Species 0.000 description 8
238000004458 analytical method Methods 0.000 description 8
230000006698 induction Effects 0.000 description 8
230000001939 inductive effect Effects 0.000 description 8
241000699666 Mus <mouse, genus> Species 0.000 description 7
108091028043 Nucleic acid sequence Proteins 0.000 description 7
239000011159 matrix material Substances 0.000 description 7
238000006386 neutralization reaction Methods 0.000 description 7
230000004044 response Effects 0.000 description 7
230000002441 reversible effect Effects 0.000 description 7
230000009471 action Effects 0.000 description 6
241000699670 Mus sp. Species 0.000 description 5
208000027697 autoimmune lymphoproliferative syndrome due to CTLA4 haploinsuffiency Diseases 0.000 description 5
230000004071 biological effect Effects 0.000 description 5
201000011510 cancer Diseases 0.000 description 5
210000004443 dendritic cell Anatomy 0.000 description 5
235000014304 histidine Nutrition 0.000 description 5
230000001965 increasing effect Effects 0.000 description 5
238000000034 method Methods 0.000 description 5
239000013612 plasmid Substances 0.000 description 5
230000028327 secretion Effects 0.000 description 5
239000002671 adjuvant Substances 0.000 description 4
230000000735 allogeneic effect Effects 0.000 description 4
239000000427 antigen Substances 0.000 description 4
102000036639 antigens Human genes 0.000 description 4
108091007433 antigens Proteins 0.000 description 4
201000010099 disease Diseases 0.000 description 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
239000002158 endotoxin Substances 0.000 description 4
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 4
201000001441 melanoma Diseases 0.000 description 4
239000002773 nucleotide Substances 0.000 description 4
125000003729 nucleotide group Chemical group 0.000 description 4
210000002966 serum Anatomy 0.000 description 4
230000000638 stimulation Effects 0.000 description 4
238000002054 transplantation Methods 0.000 description 4
230000003612 virological effect Effects 0.000 description 4
IJJWOSAXNHWBPR-HUBLWGQQSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-(6-hydrazinyl-6-oxohexyl)pentanamide Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)NCCCCCC(=O)NN)SC[C@@H]21 IJJWOSAXNHWBPR-HUBLWGQQSA-N 0.000 description 3
102000002265 Human Growth Hormone Human genes 0.000 description 3
108010000521 Human Growth Hormone Proteins 0.000 description 3
239000000854 Human Growth Hormone Substances 0.000 description 3
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 3
241001529936 Murinae Species 0.000 description 3
235000004279 alanine Nutrition 0.000 description 3
230000003321 amplification Effects 0.000 description 3
230000000259 anti-tumor effect Effects 0.000 description 3
239000000872 buffer Substances 0.000 description 3
238000005119 centrifugation Methods 0.000 description 3
238000010276 construction Methods 0.000 description 3
RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 3
239000000411 inducer Substances 0.000 description 3
239000003112 inhibitor Substances 0.000 description 3
210000004185 liver Anatomy 0.000 description 3
PKAHQJNJPDVTDP-UHFFFAOYSA-N methyl cyclopropanecarboxylate Chemical compound COC(=O)C1CC1 PKAHQJNJPDVTDP-UHFFFAOYSA-N 0.000 description 3
238000012544 monitoring process Methods 0.000 description 3
230000003472 neutralizing effect Effects 0.000 description 3
238000003199 nucleic acid amplification method Methods 0.000 description 3
102000005962 receptors Human genes 0.000 description 3
108020003175 receptors Proteins 0.000 description 3
210000004881 tumor cell Anatomy 0.000 description 3
108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
108090000669 Annexin A4 Proteins 0.000 description 2
102100034612 Annexin A4 Human genes 0.000 description 2
108090000426 Caspase-1 Proteins 0.000 description 2
102100035904 Caspase-1 Human genes 0.000 description 2
108091026890 Coding region Proteins 0.000 description 2
108091035707 Consensus sequence Proteins 0.000 description 2
230000004544 DNA amplification Effects 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
108010051696 Growth Hormone Proteins 0.000 description 2
102000008300 Mutant Proteins Human genes 0.000 description 2
108010021466 Mutant Proteins Proteins 0.000 description 2
102000001708 Protein Isoforms Human genes 0.000 description 2
108010029485 Protein Isoforms Proteins 0.000 description 2
238000007792 addition Methods 0.000 description 2
230000001580 bacterial effect Effects 0.000 description 2
230000008901 benefit Effects 0.000 description 2
238000007664 blowing Methods 0.000 description 2
230000001413 cellular effect Effects 0.000 description 2
239000012228 culture supernatant Substances 0.000 description 2
102000003675 cytokine receptors Human genes 0.000 description 2
108010057085 cytokine receptors Proteins 0.000 description 2
230000007123 defense Effects 0.000 description 2
238000012217 deletion Methods 0.000 description 2
238000011161 development Methods 0.000 description 2
238000001962 electrophoresis Methods 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000000605 extraction Methods 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
238000009169 immunotherapy Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
208000015181 infectious disease Diseases 0.000 description 2
230000002401 inhibitory effect Effects 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
231100000518 lethal Toxicity 0.000 description 2
230000001665 lethal effect Effects 0.000 description 2
208000032839 leukemia Diseases 0.000 description 2
150000002632 lipids Chemical class 0.000 description 2
229920006008 lipopolysaccharide Polymers 0.000 description 2
210000002540 macrophage Anatomy 0.000 description 2
244000005700 microbiome Species 0.000 description 2
230000037361 pathway Effects 0.000 description 2
YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
238000012545 processing Methods 0.000 description 2
210000001236 prokaryotic cell Anatomy 0.000 description 2
238000000746 purification Methods 0.000 description 2
230000002829 reductive effect Effects 0.000 description 2
108091008146 restriction endonucleases Proteins 0.000 description 2
239000000243 solution Substances 0.000 description 2
241000894007 species Species 0.000 description 2
210000000952 spleen Anatomy 0.000 description 2
238000012360 testing method Methods 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
238000002560 therapeutic procedure Methods 0.000 description 2
238000001890 transfection Methods 0.000 description 2
238000012546 transfer Methods 0.000 description 2
238000011144 upstream manufacturing Methods 0.000 description 2
238000002255 vaccination Methods 0.000 description 2
SYSZENVIJHPFNL-UHFFFAOYSA-N (alpha-D-mannosyl)7-beta-D-mannosyl-diacetylchitobiosyl-L-asparagine, isoform B (protein) Chemical compound COC1=CC=C(I)C=C1 SYSZENVIJHPFNL-UHFFFAOYSA-N 0.000 description 1
102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
241000534414 Anotopterus nikparini Species 0.000 description 1
241000726103 Atta Species 0.000 description 1
208000023275 Autoimmune disease Diseases 0.000 description 1
101100454194 Caenorhabditis elegans mei-1 gene Proteins 0.000 description 1
101100401100 Caenorhabditis elegans mes-1 gene Proteins 0.000 description 1
241000283707 Capra Species 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
102000000844 Cell Surface Receptors Human genes 0.000 description 1
108010001857 Cell Surface Receptors Proteins 0.000 description 1
108020004705 Codon Proteins 0.000 description 1
238000011238 DNA vaccination Methods 0.000 description 1
241000887108 Dicoma Species 0.000 description 1
101100163433 Drosophila melanogaster armi gene Proteins 0.000 description 1
101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
102000004190 Enzymes Human genes 0.000 description 1
108090000790 Enzymes Proteins 0.000 description 1
241000283074 Equus asinus Species 0.000 description 1
101710134987 Esterase 6 Proteins 0.000 description 1
UOACKFBJUYNSLK-XRKIENNPSA-N Estradiol Cypionate Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H](C4=CC=C(O)C=C4CC3)CC[C@@]21C)C(=O)CCC1CCCC1 UOACKFBJUYNSLK-XRKIENNPSA-N 0.000 description 1
102000018997 Growth Hormone Human genes 0.000 description 1
241000282412 Homo Species 0.000 description 1
241001562081 Ikeda Species 0.000 description 1
108060003951 Immunoglobulin Proteins 0.000 description 1
206010061218 Inflammation Diseases 0.000 description 1
102000013462 Interleukin-12 Human genes 0.000 description 1
108010065805 Interleukin-12 Proteins 0.000 description 1
102000015696 Interleukins Human genes 0.000 description 1
108010063738 Interleukins Proteins 0.000 description 1
102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
241000124008 Mammalia Species 0.000 description 1
206010027455 Metastases to kidney Diseases 0.000 description 1
101100460719 Mus musculus Noto gene Proteins 0.000 description 1
239000000020 Nitrocellulose Substances 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
241000283973 Oryctolagus cuniculus Species 0.000 description 1
108091005804 Peptidases Proteins 0.000 description 1
241001387976 Pera Species 0.000 description 1
102000003992 Peroxidases Human genes 0.000 description 1
108010093965 Polymyxin B Proteins 0.000 description 1
108010040201 Polymyxins Proteins 0.000 description 1
208000037062 Polyps Diseases 0.000 description 1
239000004365 Protease Substances 0.000 description 1
208000006265 Renal cell carcinoma Diseases 0.000 description 1
102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
210000001744 T-lymphocyte Anatomy 0.000 description 1
241000710209 Theiler's encephalomyelitis virus Species 0.000 description 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
241000533793 Tipuana tipu Species 0.000 description 1
108010067390 Viral Proteins Proteins 0.000 description 1
101100187345 Xenopus laevis noto gene Proteins 0.000 description 1
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
239000002253 acid Substances 0.000 description 1
230000004913 activation Effects 0.000 description 1
238000001261 affinity purification Methods 0.000 description 1
125000003295 alanine group Chemical group N[C@@H](C)C(=O)* 0.000 description 1
229960000723 ampicillin Drugs 0.000 description 1
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 1
238000010171 animal model Methods 0.000 description 1
238000011224 anti-cancer immunotherapy Methods 0.000 description 1
230000000947 anti-immunosuppressive effect Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004204 blood vessel Anatomy 0.000 description 1
201000008275 breast carcinoma Diseases 0.000 description 1
238000002619 cancer immunotherapy Methods 0.000 description 1
238000004113 cell culture Methods 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
210000004978 chinese hamster ovary cell Anatomy 0.000 description 1
238000010367 cloning Methods 0.000 description 1
238000004939 coking Methods 0.000 description 1
230000000295 complement effect Effects 0.000 description 1
231100000433 cytotoxic Toxicity 0.000 description 1
230000001472 cytotoxic effect Effects 0.000 description 1
230000003013 cytotoxicity Effects 0.000 description 1
231100000135 cytotoxicity Toxicity 0.000 description 1
230000037430 deletion Effects 0.000 description 1
238000004925 denaturation Methods 0.000 description 1
230000036425 denaturation Effects 0.000 description 1
238000001514 detection method Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010494 dissociation reaction Methods 0.000 description 1
230000005593 dissociations Effects 0.000 description 1
230000035622 drinking Effects 0.000 description 1
229940079593 drug Drugs 0.000 description 1
239000003814 drug Substances 0.000 description 1
239000003480 eluent Substances 0.000 description 1
230000002708 enhancing effect Effects 0.000 description 1
210000003527 eukaryotic cell Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
239000013613 expression plasmid Substances 0.000 description 1
239000013604 expression vector Substances 0.000 description 1
239000000284 extract Substances 0.000 description 1
238000010304 firing Methods 0.000 description 1
-1 for example Proteins 0.000 description 1
230000004927 fusion Effects 0.000 description 1
238000012239 gene modification Methods 0.000 description 1
230000005017 genetic modification Effects 0.000 description 1
235000013617 genetically modified food Nutrition 0.000 description 1
239000000122 growth hormone Substances 0.000 description 1
210000002443 helper t lymphocyte Anatomy 0.000 description 1
150000002411 histidines Chemical class 0.000 description 1
230000007124 immune defense Effects 0.000 description 1
208000026278 immune system disease Diseases 0.000 description 1
102000018358 immunoglobulin Human genes 0.000 description 1
230000004054 inflammatory process Effects 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
229940117681 interleukin-12 Drugs 0.000 description 1
238000002955 isolation Methods 0.000 description 1
210000001865 kupffer cell Anatomy 0.000 description 1
210000000265 leukocyte Anatomy 0.000 description 1
239000003446 ligand Substances 0.000 description 1
108020001756 ligand binding domains Proteins 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
239000007791 liquid phase Substances 0.000 description 1
210000004698 lymphocyte Anatomy 0.000 description 1
239000003550 marker Substances 0.000 description 1
235000019988 mead Nutrition 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
239000012528 membrane Substances 0.000 description 1
230000011987 methylation Effects 0.000 description 1
238000007069 methylation reaction Methods 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
230000001400 myeloablative effect Effects 0.000 description 1
210000000822 natural killer cell Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
229920001220 nitrocellulos Polymers 0.000 description 1
150000007523 nucleic acids Chemical group 0.000 description 1
231100000590 oncogenic Toxicity 0.000 description 1
230000002246 oncogenic effect Effects 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
210000002997 osteoclast Anatomy 0.000 description 1
BVURVTVDNWSNFN-UHFFFAOYSA-N pepap Chemical compound C1CC(OC(=O)C)(C=2C=CC=CC=2)CCN1CCC1=CC=CC=C1 BVURVTVDNWSNFN-UHFFFAOYSA-N 0.000 description 1
210000005259 peripheral blood Anatomy 0.000 description 1
239000011886 peripheral blood Substances 0.000 description 1
210000004976 peripheral blood cell Anatomy 0.000 description 1
210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
108040007629 peroxidase activity proteins Proteins 0.000 description 1
210000002826 placenta Anatomy 0.000 description 1
229920000024 polymyxin B Polymers 0.000 description 1
229960005266 polymyxin b Drugs 0.000 description 1
230000008569 process Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000009465 prokaryotic expression Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
230000006337 proteolytic cleavage Effects 0.000 description 1
238000011155 quantitative monitoring Methods 0.000 description 1
238000011160 research Methods 0.000 description 1
235000002020 sage Nutrition 0.000 description 1
239000013049 sediment Substances 0.000 description 1
238000000527 sonication Methods 0.000 description 1
238000010186 staining Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
239000006228 supernatant Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000007910 systemic administration Methods 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
230000008685 targeting Effects 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
230000002110 toxicologic effect Effects 0.000 description 1
231100000027 toxicology Toxicity 0.000 description 1
238000009966 trimming Methods 0.000 description 1
210000002700 urine Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Toxicology (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
Virology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Peptides Or Proteins (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)

UA2003109084A 2001-03-08 2002-08-03 Il-18 mutant polypeptide, extracted dna coded il-18 mutant polypeptide, vector and pharmaceutical composition UA79235C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US27432701P	2001-03-08	2001-03-08
PCT/IB2002/002344 WO2002101049A2 (en)	2001-03-08	2002-03-08	Interleukin-18 mutants, their production and use

Publications (1)

Publication Number	Publication Date
UA79235C2 true UA79235C2 (en)	2007-06-11

Family

ID=23047735

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA2003109084A UA79235C2 (en)	2001-03-08	2002-08-03	Il-18 mutant polypeptide, extracted dna coded il-18 mutant polypeptide, vector and pharmaceutical composition

Country Status (18)

Country	Link
US (2)	US7524488B2 (de)
EP (1)	EP1392830B1 (de)
JP (1)	JP2004530432A (de)
KR (1)	KR100862136B1 (de)
CN (1)	CN100503829C (de)
AT (1)	ATE315647T1 (de)
AU (1)	AU2002324249B2 (de)
BR (1)	BRPI0207933B8 (de)
CA (1)	CA2438851C (de)
DE (1)	DE60208692T2 (de)
DK (1)	DK1392830T3 (de)
EA (1)	EA005769B1 (de)
ES (1)	ES2251610T3 (de)
IL (2)	IL157800A0 (de)
MX (1)	MXPA03008110A (de)
SI (1)	SI1392830T1 (de)
UA (1)	UA79235C2 (de)
WO (1)	WO2002101049A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ATE500267T1 (de)	2003-07-21	2011-03-15	Transgene Sa	Multifunktionelle cytokine
DE602004031341D1 (de)	2003-07-21	2011-03-24	Transgene Sa	Multifunktionelle cytokine
DK1689777T3 (da) *	2003-11-05	2007-06-11	Ares Trading Sa	Fremgangsmåde til oprensning af il18-bindende protein
WO2005097998A2 (en) *	2004-03-31	2005-10-20	Regeneron Pharmaceuticals, Inc.	Il-18 specific polypeptides and therapeutic uses thereof
AU2006254103B2 (en)	2005-06-03	2012-09-06	Ares Trading S.A.	Production of recombinant IL-18 binding protein
AU2006256763B2 (en)	2005-06-10	2012-08-02	Ares Trading S.A.	Process for the purification of IL-18 binding protein
CN101177454B (zh) *	2007-05-09	2010-09-22	郑骏年	Il-18突变体多肽及制备及用途
WO2012078936A2 (en) *	2010-12-10	2012-06-14	Glaxosmithkline Llc	Methods to produce a purified peptide chain fraction
IL272635B2 (en) *	2017-09-06	2024-02-01	Univ Yale	Variants of interleukin-18 and methods of use
US12029778B2 (en)	2019-05-13	2024-07-09	Yale University	Interleukin-18 mimics and methods of use
JP2021170968A (ja) *	2020-04-22	2021-11-01	国立大学法人長崎大学	マウスｉｌ−１８の製造方法及びそのための組換えｄｎａ
CA3189327A1 (en) *	2020-08-19	2022-02-24	Vijaya Raghavan PATTABIRAMAN	Modified il-18 polypeptides and uses thereof
JP2023550545A (ja)	2020-11-02	2023-12-01	シムハ・アイエル－１８・インコーポレイテッド	インターロイキン－１８バリアントおよび使用の方法
JP7812094B2 (ja) *	2021-02-10	2026-02-09	国立大学法人長崎大学	新規ヒトインターロイキン－１８変異体及びその用途
US20230146665A1 (en)	2021-07-27	2023-05-11	Xencor, Inc.	Il-18-fc fusion proteins
JP7849832B2 (ja)	2021-08-06	2026-04-22	国立大学法人長崎大学	がんの治療剤
WO2023056193A2 (en) *	2021-09-29	2023-04-06	Chimera Bioengineering, Inc.	Il-18 variants and uses thereof
WO2023118497A1 (en) *	2021-12-22	2023-06-29	Pieris Pharmaceuticals Gmbh	Novel il-18 variants
AU2023226005A1 (en)	2022-02-23	2024-08-29	Bright Peak Therapeutics Ag	Activatable il-18 polypeptides
CA3244053A1 (en) *	2022-02-23	2023-08-31	Bright Peak Therapeutics Ag	MODIFIED IL-18 POLYPEPTIDES
AU2023226512A1 (en)	2022-02-23	2024-08-29	Bright Peak Therapeutics Ag	Immune antigen specific il-18 immunocytokines and uses thereof
WO2024044780A1 (en) *	2022-08-26	2024-02-29	Sutro Biopharma, Inc.	Interleukin-18 variants and uses thereof
WO2024102693A2 (en)	2022-11-07	2024-05-16	Xencor, Inc.	Il-18-fc fusion proteins
WO2025085447A1 (en)	2023-10-17	2025-04-24	Xencor, Inc.	Pd-1 targeted il18-fc fusion proteins
US12134635B1 (en)	2023-12-29	2024-11-05	Sonnet BioTherapeutics, Inc.	Interleukin 18 (IL-18) variants and fusion proteins comprising same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP4024366B2 (ja) *	1996-11-29	2007-12-19	株式会社林原生物化学研究所	ポリペプチド
TWI227136B (en) *	1998-05-21	2005-02-01	Smithkline Beecham Corp	Novel pharmaceutical composition for the prevention and/or treatment of cancer
IL129427A0 (en)	1999-04-13	2000-02-17	Yeda Res & Dev	Preparation of biologically active molecules

2002
- 2002-03-08 WO PCT/IB2002/002344 patent/WO2002101049A2/en not_active Ceased
- 2002-03-08 CN CNB02809803XA patent/CN100503829C/zh not_active Expired - Lifetime
- 2002-03-08 CA CA2438851A patent/CA2438851C/en not_active Expired - Lifetime
- 2002-03-08 AT AT02758668T patent/ATE315647T1/de active
- 2002-03-08 SI SI200230280T patent/SI1392830T1/sl unknown
- 2002-03-08 MX MXPA03008110A patent/MXPA03008110A/es active IP Right Grant
- 2002-03-08 IL IL15780002A patent/IL157800A0/xx unknown
- 2002-03-08 JP JP2003503799A patent/JP2004530432A/ja active Pending
- 2002-03-08 EP EP02758668A patent/EP1392830B1/de not_active Expired - Lifetime
- 2002-03-08 EA EA200300987A patent/EA005769B1/ru not_active IP Right Cessation
- 2002-03-08 AU AU2002324249A patent/AU2002324249B2/en not_active Expired
- 2002-03-08 ES ES02758668T patent/ES2251610T3/es not_active Expired - Lifetime
- 2002-03-08 US US10/094,153 patent/US7524488B2/en not_active Expired - Lifetime
- 2002-03-08 KR KR1020037011581A patent/KR100862136B1/ko not_active Expired - Lifetime
- 2002-03-08 BR BR0207933-0 patent/BRPI0207933B8/pt not_active IP Right Cessation
- 2002-03-08 DE DE60208692T patent/DE60208692T2/de not_active Expired - Lifetime
- 2002-03-08 DK DK02758668T patent/DK1392830T3/da active
- 2002-08-03 UA UA2003109084A patent/UA79235C2/uk unknown
2003
- 2003-09-08 IL IL157800A patent/IL157800A/en unknown
2009
- 2009-03-16 US US12/404,458 patent/US7875709B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
JP2004530432A (ja)	2004-10-07
WO2002101049A2 (en)	2002-12-19
KR100862136B1 (ko)	2008-10-09
MXPA03008110A (es)	2003-12-12
CN1764723A (zh)	2006-04-26
WO2002101049A3 (en)	2003-12-18
EA200300987A1 (ru)	2004-02-26
BRPI0207933B8 (pt)	2021-05-25
US7524488B2 (en)	2009-04-28
US7875709B2 (en)	2011-01-25
BRPI0207933B1 (pt)	2020-11-24
EP1392830B1 (de)	2006-01-11
IL157800A0 (en)	2004-03-28
HK1084151A1 (zh)	2006-07-21
EA005769B1 (ru)	2005-06-30
IL157800A (en)	2009-08-03
CA2438851C (en)	2011-07-26
KR20030088448A (ko)	2003-11-19
AU2002324249B2 (en)	2007-04-05
ATE315647T1 (de)	2006-02-15
BR0207933A (pt)	2004-03-02
US20020169291A1 (en)	2002-11-14
CA2438851A1 (en)	2002-12-19
US20090286855A1 (en)	2009-11-19
SI1392830T1 (sl)	2006-06-30
DE60208692T2 (de)	2006-07-13
CN100503829C (zh)	2009-06-24
DE60208692D1 (de)	2006-04-06
EP1392830A2 (de)	2004-03-03
ES2251610T3 (es)	2006-05-01
DK1392830T3 (da)	2006-05-08

Publication	Publication Date	Title
UA79235C2 (en)	2007-06-11	Il-18 mutant polypeptide, extracted dna coded il-18 mutant polypeptide, vector and pharmaceutical composition
Chen et al.	1992	T-cell immunity to the joining region of p210BCR-ABL protein.
Waldmann	1986	The structure, function, and expression of interleukin-2 receptors on normal and malignant lymphocytes
CN119768509A (zh)	2025-04-04	肿瘤激活的异体反应性和异种反应性t细胞及其在癌症免疫治疗中的应用
CA2906587C (en)	2023-02-14	Compositions and methods for use of recombinant t cell receptors for direct recognition of tumor antigen
Fallarino et al.	2000	Th1 and Th2 cell clones to a poorly immunogenic tumor antigen initiate CD8+ T cell-dependent tumor eradication in vivo
EP3842051A1 (de)	2021-06-30	Therapeutikum mit nukleinsäure und car-modifizierter immunzelle und seine verwendung
CA3119472A1 (en)	2020-05-28	Split interleukin mimetics and their use
CN107428816A (zh)	2017-12-01	针对肿瘤抗原ny‑eso‑1的mhc i和mhc ii‑限制表位的癌症的组合t细胞受体基因疗法
EP4613762A1 (de)	2025-09-10	Kras_g12v mutierter antigenspezifischer tcr und umgeleitete cd4-t-zelle zur koexpression davon und cd8
CN113727720A (zh)	2021-11-30	用于治疗表达cldn6的癌症的嵌合抗原受体修饰的细胞
CN108866088B (zh)	2023-06-09	靶向cll-1嵌合抗原受体及其用途
CN109320615A (zh)	2019-02-12	靶向新型bcma的嵌合抗原受体及其用途
CN109423495A (zh)	2019-03-05	一种双靶向嵌合抗原受体及其用途
KR20220052987A (ko)	2022-04-28	Ebv 유래 항원에 특이적인 tcr 작제물
US11098283B2 (en)	2021-08-24	T cells modified to overexpress c-Myb
Fujii et al.	2022	Cancer immunotherapy using artificial adjuvant vector cells to deliver NY‐ESO‐1 antigen to dendritic cells in situ
CN116970058B (zh)	2023-12-15	针对tp53基因r249s突变的肿瘤新抗原多肽及其应用
US12227558B2 (en)	2025-02-18	Modulators of notch signaling and methods of use thereof
Xu et al.	2022	Interleukins in the treatment of melanoma
JPWO2001011044A1 (ja)	2003-03-04	腫瘍抗原
WO2025189363A1 (zh)	2025-09-18	一种t细胞受体(tcr)及其用途
AU2006327514B2 (en)	2010-04-15	DNA vaccine for cancer therapy
CN110564749A (zh)	2019-12-13	靶向egfr的嵌合抗原受体及其用途
US20240009239A1 (en)	2024-01-11	Therapeutic targeting of mesothelin in acute myeloid leukemia with chimeric antigen receptor t cell therapy